Țară: Canada
Limbă: engleză
Sursă: Health Canada
SEVELAMER CARBONATE
INTELLIPHARM INC
V03AE02
SEVELAMER
800MG
TABLET
SEVELAMER CARBONATE 800MG
ORAL
100
Prescription
PHOSPHATE-REMOVING AGENTS
Active ingredient group (AIG) number: 0152763001; AHFS:
CANCELLED PRE MARKET
2021-06-10
_Intelli-Sevelamer Product Monograph _ _Page 1 of 24 _ PRODUCT MONOGRAPH PR INTELLI-SEVELAMER SEVELAMER CARBONATE TABLETS 800 mg Phosphate Binder ATC code: VO3A EO2 Intellipharm Inc. 299 Chemin du lac Cardin Lantier, Quebec J0T 1V0 DATE OF PREPARATION: DECEMBER 19, 2018 SUBMISSION CONTROL NO.: 222726 _Intelli-Sevelamer Product Monograph _ _Page 2 of 24 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................3 ADVERSE REACTIONS ....................................................................................................5 DRUG INTERACTIONS ....................................................................................................7 DOSAGE AND ADMINISTRATION ................................................................................8 OVERDOSAGE ................................................................................................................10 ACTION AND CLINICAL PHARMACOLOGY ............................................................10 STORAGE AND STABILITY ..........................................................................................11 SPECIAL HANDLING INSTRUCTIONS .......................................................................11 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................11 PART II: SCIENTIFIC INFORMATION ................................................................................13 PHARMACEUTICAL INFORMATION ..........................................................................13 CLINICAL TRIALS ...................... Citiți documentul complet